{"id":"W3131078121","doi":"10.1158/1538-7445.sabcs20-pd2-07","title":"Abstract PD2-07: Alpelisib + letrozole in patients with <i>PIK3CA-</i>mutated, hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) previously treated with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + fulvestrant: BYLieve study results","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Letrozole; Cohort; Medicine; Fulvestrant; Internal medicine; Oncology; Breast cancer; Clinical endpoint; Cancer; Gynecology; Clinical trial; Estrogen receptor; Aromatase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001172052,0.000868748,0.001263132,0.0002055116,0.0002343511,0.001342802,0.0005168846,0.0007631021,0.005326026],"category_scores_gemma":[0.0008920174,0.0002278103,0.001727312,0.0002965316,0.0004778263,0.0007698892,0.0002974782,0.002518394,0.0009775949],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009222135,"about_ca_system_score_gemma":0.001278147,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001151847,"about_ca_topic_score_gemma":0.003073929,"domain_scores_codex":[0.9994742,0.0002627318,0.00003298849,0.00008944253,0.00006834215,0.00007226008],"domain_scores_gemma":[0.9994222,0.000106903,0.00009887077,0.00004477456,0.00006597654,0.0002612999],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.834909,0.01207283,0.0108565,0.001081275,0.004378508,0.0001277456,0.0001146084,0.001612627,0.01523253,0.0003940825,0.01143446,0.1077859],"study_design_scores_gemma":[0.625268,0.3060081,0.03820584,0.000190544,0.005119037,0.0003943393,0.0001183379,0.001909666,0.006770207,0.0006031478,0.01534796,0.00006488984],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9741825,0.006065007,0.0006326241,0.001746505,0.0002621388,0.001050398,0.006262823,0.0001813247,0.00961661],"genre_scores_gemma":[0.9825335,0.002308073,0.0008510309,0.001550426,0.0002387018,0.000655842,0.00831916,0.00003708503,0.00350608],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005326026,"threshold_uncertainty_score":0.01781738,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02330723514965225,"score_gpt":0.3372044939661631,"score_spread":0.3138972588165109,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}